The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA®, on the German market. XATEPA® is a cannabinoid-based analgesic drug.

COPENHAGEN, Denmark, May 4, 2023 /PRNewswire/ — Tetra Pharm Technologies develops and manufactures drugs that target the endocannabinoid system for the treatment of neuropathic pain, sclerosis, and mental health disorders.

“The launch of our first product represents an important and significant milestone for Tetra Pharm Technologies. From a business perspective, it provides us with the opportunity to further strengthen the company’s long-term research and development efforts, which is our primary focus.” said Martin Rose, CEO of Tetra Pharm Technologies.

Tetra Pharm Technologies plans to expand the sales of XATEPA® and launch the drug in several additional European and foreign markets in the near future.

“The suitability of the drug delivery system is often neglected at the expense of cannabinoid bioavailability. Our XATEPA® sublingual spray solution is designed as a putative enabling technology to provide optimal conditions for cannabinoid absorption and thus , efficacy. From a pharmaceutical science perspective, we are very proud of this achievement, and look forward to launching more innovative products targeting the endocannabinoid system,” said Dr. Morten Allesø, Chief Scientific Officer of Tetra Pharm Technologies.

Tetra Pharm Technologies has signed an agreement with PHOENIX Pharma-Einkauf GmbH for the distribution of XATEPA® in Germany. PHOENIX Pharma-Einkauf GmbH is one of the largest wholesale distributors of pharmaceutical and healthcare products in Europe.

“Germany is Europe’s largest market for cannabinoid-based medicines, and we have positive expectations for the sales of XATEPA®. The partnership with PHOENIX Pharma-Einkauf GmbH regarding distribution to German pharmacies ensures access to the product for all doctors and their patients, and because we have cut out the middlemen, we can deliver the product at a fair price,” said Martin Caspersen, commercial director of Tetra Pharm Technologies.

About Tetra Pharm Technologies ApS

Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with the vision to be a leader in research and development of drugs for the treatment of diseases related to the endocannabinoid system. For more information visit

For more information: Martin 45 6122 4241


View original content: